GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions.
Latest Information Update: 02 Aug 2022
Price :
$35 *
At a glance
- Drugs Ozenoxacin (Primary)
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Therapeutic Use
- Sponsors Ferrer
- 30 Jul 2022 This trial has been completed in France, according to European Clinical Trials Database record (26 Mar 2010).
- 30 Jul 2022 This trial has been completed in Spain, according to European Clinical Trials Database record (26 Mar 2010).
- 23 Feb 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2008-007055-28).